Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 3p25 3 Microdeletion Syndrome C5437630
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 3p25 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
3p25 3 Microdeletion Syndrome C5437630
A genetic condition from missing chromosome material at 3p25, linked to developmental delays, distinctive features, and sometimes heart or other organ involvement.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
3p25 3 Microdeletion Syndrome C5437630
0-null
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
3p25 3 Microdeletion Syndrome C5437630
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
3p25 3 Microdeletion Syndrome C5437630
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
3p25 3 Microdeletion Syndrome C5437630
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3p25 3 Microdeletion Syndrome C5437630
congenital
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3p25 3 Microdeletion Syndrome C5437630
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 3p25-3-microdeletion-syndrome-C5437630 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3p25 3 Microdeletion Syndrome C5437630 | Discriminating power |
|---|---|---|---|
| Developmental delay | Early neurologic delay linked to impaired serine production. | Developmental delay associated with missing 3p25.3 material. | Low |
| Seizures and movement difficulty | Seizures and movement problems are described features. | Not established from the supplied description. | Moderate |
| Congenital features or organ involvement | Primarily described as a metabolic nervous-system disorder. | Distinctive features and sometimes heart or other organ involvement. | Moderate |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Infant or young child with seizures and developmental delay
Fits the described neurologic metabolic pattern and early onset.
Moderate
Suspected disorder of serine synthesis
The condition specifically impairs serine production.
High
Need to consider metabolic treatment
Source management includes serine supplementation and anticonvulsants as needed.
Moderate
Choose 3p25 3 Microdeletion Syndrome C5437630 when
Developmental delay with distinctive congenital features
These features are described for the microdeletion.
Moderate
Possible heart or other organ anomalies
Organ involvement is mentioned, although not always present.
Moderate
Suspected chromosomal copy-number change
The condition is defined by missing 3p25 material.
High
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3p25 3 Microdeletion Syndrome C5437630 | Interpretation |
|---|---|---|---|
| Amino acid studies | May support reduced serine; exact cutoffs are not supplied. | No characteristic amino acid abnormality is established here. | Abnormal results require specialist confirmation and do not alone prove the diagnosis. |
| Chromosomal microarray | Not expected to identify this metabolic enzyme disorder. | May detect a 3p25.3 microdeletion. | A detected deletion needs clinical correlation and genetic counseling. |
| Gene or enzyme evaluation | May support PHGDH-related serine-synthesis deficiency. | Does not replace testing for chromosomal material loss. | Choose testing according to metabolic versus chromosomal suspicion. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- Described as severe and chronic; exact outcomes are not established.
- Factors
- Neurologic involvement, seizures, and response to individualized care may matter.
3p25 3 Microdeletion Syndrome C5437630
- Outcome
- Described as moderate and chronic, with variable organ involvement.
- Factors
- Extent of deletion effects and organ findings may influence course.
Time frame: Often recognized in early life; long-term course varies.
Prognosis should be individualized; comparative mortality is not supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic complications | Seizures, developmental delay, and movement difficulty are described. Developmental delay is described; seizures are not established here. Neurologic impact should be assessed individually. |
| Organ involvement | Not established beyond the described nervous-system effects. Heart or other organs may sometimes be involved. Targeted evaluation depends on clinical findings. |
| Treatment-related burden | May require ongoing supplementation and seizure treatment. Care is generally supportive and organ-specific. No doses or outcome rates are established by this source. |
Patient education highlights
- HighDifferent causes
One is a metabolic serine-production disorder; the other is a chromosomal microdeletion.
- HighTesting
Amino acid or enzyme findings and chromosomal testing answer different questions.
- MediumFollow-up
Both are chronic and need clinician-guided developmental and medical monitoring.